Gene-associated with retinoid-interferon induced mortality-19 (GRIM-19), a STAT3-inhibitory protein, was isolated as a growthsuppressive gene product using a genome-wide expression knockdown screen. We and others have shown a loss of expression and occurrence of mutations in the GRIM-19 gene in a variety of primary human cancers, indicating its potential role as tumor suppressor. To help investigate its role in tumor development in vivo, we generated a genetically modified mouse in which Grim-19 can be conditionally inactivated. Deletion of Grim-19 in the skin significantly increased the susceptibility of mice to chemical carcinogenesis, resulting in development of squamous cell carcinomas. These tumors had high Stat3 activity and an increased expression of Stat3-responsive genes. Loss of Grim-19 also caused mitochondrial electron transport dysfunction resulting from failure to assemble electron transport chain complexes and altered the expression of several cellular genes involved in glycolysis. Surprisingly, the deletion of a single copy of the Grim-19 gene was sufficient to promote carcinogenesis and formation of invasive squamous cell carcinomas. These observations highlight the critical role of GRIM-19 as a tumor suppressor.
cytokines | glucose metabolism | oxidative phosphorylation | immune response I t is now clear that multiple tumor suppressors are inactivated in a cell before the establishment of malignant state. The Hanahan-Weinberg model (1) suggests that at least 10 different genetic and microenvironmental alterations in and around a precancerous mammalian cell are necessary for successfully establishing a tumor. These alterations include the acquisition of resistance to apoptosis, enhanced motility, and angiogenesis; alteration in glucose metabolism; activation of tumor-proliferating inflammation; and suppression of antitumor immunity. Interestingly, a number of these processes are dependent on cytokines and/or other secretory factors, which alter tumor growth by changing the milieu around the tumor. Some cytokines inhibit and others promote tumor growth.
The IFN group of cytokines is a major player in suppressing neoplastic cell development (2) . Endogenous IFNs act as sentinels against tumor development (3). IFNs not only induce growth-suppressive gene expression in the target tumor cells but also promote immune cell-mediated attack. Depending upon the target cell, IFNs can inhibit the progression of the cell cycle or can evoke apoptosis. IFN signaling defects are common in several human cancers (4) . In certain cases IFN response is essential for tumor therapy with DNA-damaging agents (5) ; in other cases the expression of an IFN-related DNA-damage signature correlates with a lack of therapeutic response (6) . Consistent with these activities, a number of IFN-regulated factors such as STAT1 (7) and the IFN-regulatory factors (IRF) IRF1 (8) , IRF7 (9) , and IRF8 (10) have been described as critical players in tumor suppression. The IRF1 and IRF8 proteins fit the classical definition of a tumor suppressor, given their loss of expression or mutation in primary human tumors and in animal models of cancer development (11, 12) . All the proteins mentioned above are transcription factors whose activity/inactivity affects numerous gene products, and the products that are relevant to tumor suppression still need to be defined.
In several clinical and preclinical models, we and others have shown that IFN in combination with other modifiers of biological response, such as retinoic acid (RA), potently suppresses tumor growth (2) . To investigate the mechanisms underlying tumor suppression, we used a genome-wide knockdown strategy and identified some potent growth suppressors. One such growth inhibitor was GRIM-19, a protein whose depletion and overexpression, respectively, promoted and suppressed tumor growth (13) . GRIM-19 binds to STAT3 and inhibits its transcriptional activity (14, 15) . Additionally, we and others have shown that GRIM-19 expression is lost in several primary tumors of lung, kidney, prostate, thyroid, ovary, colon, esophagus, and brain. More recently, we identified functionally inactivating somatic mutations of GRIM-19 disrupting anti-STAT3 activity in certain human squamous oral cancers (16) . To understand the importance of GRIM-19 in tumorigenesis, we developed a genetically modified mouse in which Grim-19 can be conditionally inactivated. Using these mice, we show that loss of a single Grim-19 allele is sufficient to promote skin tumorigenesis. These tumors exhibited mitochondrial respiratory dysfunction and altered energy metabolism. A number of genes associated with oncogenic glycolysis also were induced in these tumors in the absence of Significance Gene-associated with retinoid-interferon induced mortality-19 (GRIM-19) is an interferon-retinoid-regulated growth suppressor that inhibits cell growth by targeting the transcription factor STAT3 for inhibition. In primary human tumors GRIM-19 is suppressed or mutated, leading to constitutive STAT3 activity and indicating the tumor-suppressive function of GRIM-19. To understand the in vivo role of Grim-19 in tumor development, we generated a Grim-19 conditional knockout mouse. We found that deletion of even a single Grim-19 allele is sufficient to augment skin tumorigenesis in mice, thus establishing a critical role for Grim-19 as a tumor suppressor. Tumors that developed in the absence of Grim-19 exhibited mitochondrial respiratory chain dysfunction, elevated glycolysis, and Stat3-responsive gene expression.
Grim-19. This study shows the importance of a STAT3 inhibitor in preventing tumorigenesis.
Results
Generation of Mice with a Conditionally Inactivated Grim-19 Allele.
Because the direct deletion of Grim-19 causes embryonic lethality, we designed a modified Grim-19 allele that would allow the generation a tissue-specific knockout. The mouse Grim-19 gene has five exons (E1-E5) and four introns. A significant portion of first two exons (E1 and E2) of Grim-19 code for the 5′ UTR of the mature transcript, with the second exon (E2) coding for first 31 amino acids. Among the four introns, introns 2 and 3 are amenable to genetic manipulation. A targeting vector was designed to insert one loxP site in intron 2 (654 bp upstream of exon 3), and the other loxP site in intron 3 (203 bp downstream of exon 3), flanked by homologous arms of 1.7 kb and 3.2 kb, respectively. The neomycin-resistance gene (Neo) and the Grim-19 gene E3 were flanked by the loxP sites. In presence of Cre recombinase, E3 and significant portions of introns 2 and 3 are deleted, and the remaining portion of the transcript goes out of frame, even though E4 and E5 are intact ( Fig. 1 A and B) .
This targeting construct was electroporated into C57BL6-derived ES cells, and positive clones were selected by Southern blot analysis (SI Appendix, Fig. S1 ). Correctly recombined stem cells were injected into the blastocysts of C57BL6 mice and transplanted into pseudopregnant mice. Several correctly targeted ES cell clones were injected into blastocysts to generate chimeras, which then were bred to obtain targeted ES cell-derived offspring carrying the modified Grim-19 allele, as determined by PCR. Homozygous and heterozygous founder mice carrying the modified Grim-19 allele (Grim-19 f ) were used for further experimentation.
Generation of a Skin-Specific Knockout. To generate a skin-specific knockout, we mated Grim-19 f/f mice with K14-CreER tam transgenic mice carrying the Cre recombinase fused to the ligandbinding domain of the estrogen receptor under the control of the Keratin-14 (K14) promoter. Binding of the estrogen antagonist, 4-hydroxy tamoxifen (4-HT), activates the Cre recombinase, which then deletes the targeted region in the Grim-19 f/f allele. We used a PCR-based approach to determine the genotype of the mice in all further experiments. To demonstrate the specificity of deletion, mice of the Grim-19 +/f and K14-Cre genotypes were treated topically with 4-HT, and genomic DNA was collected from various tissues and subjected to PCR with allelespecific primers (SI Appendix, Table S1 ). In this experiment deletion generates heterozygous mice. PCR with wild-type ( + ) and floxed ( f ) allele-specific primers yielded the expected 353-and 200-bp products, respectively, in all tissues except skin, in which the 200-bp product was not observed. When the same DNA samples were used for PCR with a primer set that detects the deleted (KO) allele, the expected 253-bp product was observed in the skin but not in other tissues (SI Appendix, Fig. S1 ). The presence of Cre gene (235 bp) was ensured by PCR.
To determine if 4-HT caused the deletion of the Grim-19 gene and its protein, f/f mice with the K14-Cre gene were treated with ethanol (vehicle) or 4-HT, and genomic DNA from the skin samples was collected and used as a template for PCR with specific primers. As shown in Fig. 1C, 4 -HT treatment specifically caused Grim-19 gene deletion, as indicated by the disappearance of the Grim-19 f/f allele and the appearance of the KO allele. These observations were confirmed further with a Western blot analysis of the skin-and liver-derived proteins. Consistent with the 4-HT-induced loss of the Grim-19 f/f allele, the expression of Grim-19 protein was absent only in the skin and not in the liver (Fig. 1D ). An equivalent expression of the K14 and actin proteins in the skin and liver, respectively, confirmed that the observed differences in GRIM-19 expression were not caused by uneven protein loading (Fig. 1D) . Henceforth, the term "Grim-19
−/− mice" connotes mice with the skinspecific deletion of Grim-19, i.e., f/f K14-Cre mice treated with 4-HT.
Loss of Grim-19 Did Not Significantly Affect Skin Differentiation. We next examined whether the deletion of Grim-19 affects skin differentiation. Skins from control (Grim-19 f/f ; notated as Grim-19 +/+ ) and 4-HT-treated (Grim-19 −/− ) mice were sectioned and stained with the skin-specific markers keratin-1, K14, and filaggrin. These sections also were counterstained separately with H&E and DAPI to visualize tissue morphology and nuclei, respectively ( Fig. 2 A and B) . Except for some slightly increased cellularity in Grim-19 −/− skins, formation of epidermis was normal in Grim-19 +/+ and Grim-19 −/− mice (arrows in Fig. 2A ). The expression of keratin-1 and filaggrin, which occur mainly in the epidermis, was comparable in both genotypes, as was K14, which is expressed in the epidermis and root follicles of the skin. In summary, Grim-19 is not required for skin differentiation or integrity.
Deletion of Grim-19 Enhances Susceptibility to Skin Tumorigenesis.
Because earlier clinical studies have shown that IFN/RA as a highly effective therapeutic on squamous cell carcinomas (SCCs) of skin and cervix (17, 18) and GRIM-19 is an IFN/RAinducible gene product that is functionally inactivated in human SCCs of these organs (16, 19) , we determined its role in the development of SCC. Functionally inactivating mutations in GRIM-19 were found in oral SCCs in tobacco users. Because skin and the oral cavity are the first contact points with environmental carcinogens and because the dermal epithelium is continuous with head and neck and cervix, we used skin as a model for tumor studies. Furthermore, two of the carcinogens found in tobacco (20) , benzanthracene and dibenzanthracene, are structural homologs of the tumor initiator 7,12-dimethylbenz[α]anthracene (DMBA). Thus, we reasoned that skin is an appropriate model for these studies. In the initial experiments groups of Grim-19 +/+ and Grim-19 −/− mice (n = 20 per group) were observed for spontaneous development of skin tumors over a period of 19 mo. During that time, no tumors were found in these mice, irrespective of their genotype. Therefore, we next asked if these mice have any increased sensitivity to chemical carcinogens. Mice (n = 24 per group) were subjected to two-stage chemical carcinogenesis using a single topical dose of DMBA and twice-weekly doses of 12-O-tetradecanoylphorbol-13-acetate (TPA) for several weeks and were observed for tumor development. This experiment used primarily female mice, because male Grim-19 −/− mice developed inguinal hernias that impeded their mobility and therefore were excluded from our studies under University of Maryland, Baltimore, Institutional Animal Care and Use Committee regulations. Indeed, it was reported earlier tamoxifen treatment promotes the formation of hernias in wild-type C57BL6 mice (21) . As shown in Fig. 3A 3B) . A majority of these initial tumors were papillomas, which shredded off after a couple of weeks.
With time, mice in both groups developed tumors (Fig. 3C ). Significantly, the tumors that developed in the Grim-19 +/+ mice were smaller (average size: ∼2 mm 3 ) than those that developed in the Grim-19 −/− mice (average size: ∼6 mm 3 ). In neither group did 100% of the mice develop tumors (Discussion). Most importantly, tumor incidence continued to be significantly higher in the Grim-19 −/− group than in the Grim-19 +/+ group over the entire period of the experiment (P < 0.0001). At the end of the experiment, only 19% of Grim-19 +/+ mice developed tumors, in sharp contrast to 66% of Grim-19 −/− mice. Thus, the loss of Grim-19 significantly increases tumor development.
Skin sections were collected from age-matched tumor-bearing and control mice at the end of week 25 and were stained with H&E. Although a single layer of epidermis and cornified epithelium could be found in the untreated skin area of Grim-19 4D ). We found this pattern of expression of both proteins in 70% of the tumors. The rise in the expression of pY 705 -Stat3 and cyclin D1 also was analyzed and quantified using Western blot analysis of the tumor extracts (Fig. 4E ). The β-catenin protein was induced in 18% of the tumors; and in 30% of the tumors the expression of enhancer zeste homolog 2 (Ezh2), a histone 3 lysine N-methyl transferase involved in chromatin repression and cell proliferation, was induced.
The cell-cell adhesion molecule E-cadherin plays a role in tissue integrity and adhesion (25) . We found that it was expressed mostly in epithelial keratinocytes of normal skins (Fig.  4F) , but E-cadherin expression also was seen in tumors. Notably, the intensity of E-cadherin expression was markedly reduced in tumors derived from Grim-19 −/− mice as compared with tumors from Grim-19 +/+ mice. This pattern of E-cadherin expression was found in 75% of the tumors analyzed and may indicate a transition from adhesive epithelium to invasive SCC. Last, 18% of Grim-19 −/− tumors expressed a higher level of β-catenin ( Fig.  4G ), a protein associated with skin tumorigenesis. Most of the β-catenin seen in the wild-type tumors was diffuse in the cytoplasm, but in Grim-19 −/− tumors β-catenin was found primarily along the membrane. The significance of this finding is unclear. The Role of Stat3 in Grim-19-Dependent Tumorigenesis. To test the biological relevance of Stat3 in driving tumorigenesis, we performed two different experiments. In the first experiment, 10 wk after tumorigenesis was initiated with DMBA/TPA (i.e., at the time when tumors begin to appear), Grim-19 −/− mice were treated s.c. with DMSO or the STAT3 inhibitor S31-201 (3 mg/kg body weight) twice weekly for an additional 5 wk. Tumor development was observed at the end of experiment. S31-201 caused a significant drop in tumor development (Fig. 5A) . These results are consistent with a previous report (26) that showed skinspecific deletion of Stat3 reduced tumor development in response to DMBA/TPA.
In the second experiment we examined whether the loss of Grim-19 accompanied by a simultaneous up-regulation of constitutively active STAT3 (STAT3C) would enhance carcinogenesis. Grim-19 f/f mice or Grim19 +/+ mice with K14-CreER tam were bred with a mouse expressing STAT3C under the control of the Rosa26 promoter. In this model, deletion of the Grim-19 f/f locus and simultaneous activation of STAT3C expression occur after the activation of Cre with 4-HT (Fig. 5B) . After we confirmed the expected genotypes (Fig. 5C ), we subjected groups of mice (n = 24) to carcinogenesis with DMBA/TPA. As controls, we used Grim-19 f/f mice and Grim19 +/+ (K14-CreER tam without STAT3C) mice. As expected, loss of Grim-19 caused a significant increase in carcinogenesis (Fig. 5D ). In the presence of STAT3C both Grim-19 
Increased Expression of Growth-Associated Genes in the Tumors of Grim-19
−/− Mice. To determine if tumor proliferation is associated with the expression of genes involved in cell growth and survival, we performed a real-time PCR analysis of transcripts coding for cyclins B1 (Ccnb1) and D1 (Ccnd1), cyclin-dependent kinase 1 (Cdk1), dihydrofolate reductase (Dhfr), an S-phase enzyme critical for purine nucleotide metabolism, and the cell-survival protein Bcl-X L (Bcl2-l1). The expression of these transcripts was increased significantly (two-to fivefold in individual tumors) in tumors derived from Grim-19 −/− mice as compared with tumors from Grim-19 +/+ mice (Fig. 6 ). All these differences were statistically significant (P < 0.01-0.001). Because of the loss of Ecadherin expression, we assumed that these tumors might have acquired an undifferentiated phenotype. Therefore, we measured the expression of the stem cell markers sex-determining region box 2 (Sox2), octamer-binding transcription factor 4 (Oct4), and Nanog in the tumors (27) . We could not detect Oct4, and Nanog in quantitative PCR (qPCR) analyses. Sox2 levels increased significantly in the Grim-19 −/− tumors as compared with the Grim-19 +/+ tumors (P < 0.02). Thus, these tumors acquired a stem cell-like feature, albeit not fully.
Loss of a Single Grim-19 Allele Increases Susceptibility to Tumorigenesis.
Based on these observations, we next investigated if the loss of a single Grim-19 allele also would increase the susceptibility to tumorigenesis. Heterozygous mice carrying wild-type and floxed alleles (Grim-19 +/f ) were mated with K14-Cre mice to generate mice lacking one Grim-19 allele (Grim-19 +/− ). Fig. 7A shows the comparative genotyping of these mice. Fig. 7B shows a representative Western blot of skin extracts from these mice. The resultant Grim-19 +/− mice (n = 17) and control Grim-19 +/+ mice (n = 18) were exposed to DMBA/TPA as described previously. Around week 13, mice in both groups developed papillomas (Fig. 7C) . At this time more Grim-19 +/− mice (18%) than Grim-19 +/+ mice (7%) had developed tumors, and thereafter there were significantly more tumor-bearing mice in the Grim-19 +/− group than in the Grim-19 +/+ group (Fig. 7D) . At the peak (weeks 19 and 20), 19% of the Grim-19 +/+ mice and 44% of Grim-19 +/− mice had tumors. This difference in the numbers of tumor-bearing mice was highly significant (P < 0.001), and, on average, there were significantly more tumors per mouse in Grim-19 +/− mice (P < 0.001) than in Grim-19 +/+ mice (Fig. 7E) . Histopathologically, these tumors ranged from keratoacanthomas to squamous cell-like carcinomas (Fig. 7F) . These tumors also were stained for pY 705 -Stat3. As expected, there were significantly (P < 0.01) higher numbers of pY 705 -STAT3 + cells in tumors from Grim-19 +/− mice than in tumors from Grim-19 +/+ mice ( Fig. 8 A and B) . This increase in active Stat3 levels in the tumors corresponded to an increase in cyclin D1 levels ( Fig. 8 C and D) . About 60% of the tumors had high pY 705 -STAT3 staining and cyclin D1 expression. As in tumors from Grim-19 −/− mice, cyclin D1 was exclusively nuclear in the tumors of Grim-19 +/− mice. No such increase in the levels of active Stat3 and cyclin D1 occurred in the normal skins. Last, the tumorigenic phenotype in Grim-19 +/− mice also was consistent with a loss of E-cadherin expression (Fig. 8E) . About 9% of these tumors had high β-catenin expression (Fig. 8F) . Thus, monoallelic loss of Grim-19 increases the susceptibility to carcinogenesis in vivo. As shown in Fig. 9A, basal −/− cells also were used for measuring glucose and lactate levels ( Fig. 9 C and D) . Significantly higher glucose consumption and lactate production were observed in Grim-19 +/− and Grim-19 −/− cells than in Grim-19 +/+ cells. As expected, such alterations in glucose and lactate were more pronounced in Grim-19 −/− cells than in Grim-19 +/− cells. Last, we have determined the levels of certain important components of various ETC complexes using the Mitoprofile Total OXPHOS monoclonal antibody mixture. The antibodies in this mixture detect NDUFB8, SDHB, UQCRC2, MTCO1, and ATP5α subunits of complexes I-V, respectively, and were chosen because they are antibodies against a subunit that is labile when its complex is not assembled. Loss of Grim-19 caused a significant decline in the levels of proteins associated with complexes I, II, IV, and V, with complexes I and IV being the most affected (Fig. 9E, Left) . The identity of the band below SDHB is unclear, because it was not present in the positive control lane (rat liver mitochondrial lysate). However, its levels also declined in the absence of Grim-19. It is likely a degradation of the product of one of the complexes or a cross-reactive protein in whole-cell lysates. Surprisingly, the levels of UQCRC2, a component of complex III, increased strongly. These differences were not to the result of differential loading of proteins. A similar analysis of the Grim-19 +/− tumors revealed a strong decline in complexes I and IV, a rise in complex III, and no effect on complexes II and V (Fig. 9E, Right) . A quantification of the bands corresponding to each complex and their relative levels are shown in Fig. 9 F and G. All differences in the levels of various complexes between Grim-19 −/− and Grim-19 +/− cells were statistically significant. Thus, loss of Grim-19 results in a significant dysfunction of mitochondrial respiration and in aberrantly active glycolysis. Notably, such differences also were observed even under conditions of monoallelic loss.
Loss of Grim-19 Promotes the Expression of Several Genes Involved in
Glycolysis. Because defects in mitochondrial respiration and production of lactic acid ( Fig. 9 C and D) were observed in Grim-19-deficient tumors, we next investigated whether changes in the genes coding for glycolytic enzymes also occurred in these tumors. Our RNA-seq data, derived from human head and neck SCCs, showed that genes coding for aldolase A (ALDOA), pyruvate kinase, liver and RBC (PKLR), glucokinase regulator (GCKR), 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 (PFKFB1), pyruvate dehydrogenase kinase, isozyme 2 (PDK2), and pyruvate dehydrogenase kinase, isozyme 4 (PDK4) were induced more than fivefold in Grim-19-deficient cells. We have reported recently that the transcript coding for the M2 isoform of pyruvate kinase (Pkm2), which is increased in v-Src-transformed rodent fibroblasts, was suppressed by GRIM-19 (28) . Therefore, using qPCR, we examined the expression of these genes in tumors that developed in Grim-19 +/+ and Grim-19 −/− mice. The Aldoa (4.2-fold), Gckr (3.6-fold), Pdk2 (4.1-fold), and Pkm2 (2.4-fold) transcripts were significantly induced in Grim-19 −/− tumors ( Fig. 10 A-D) . Interestingly, expression of Pdk4 was repressed significantly (Fig. 10E ) in the absence of Grim-19. Because the Pklr and Pfkfb1 primers did not yield any detectable products, we did not present those data here.
Our RNA-seq analysis of Grim-19-deleted mouse embryonic fibroblasts showed that several genes are up-regulated in the absence of Grim-19 and others are down-regulated ( Table 1) . The expression of ATP-binding cassette subfamily B member 5 (Abcb5), POU domain, class 2, transcription factor 2 (Pou2f2), oligodendrocyte transcription factor 1 (Olig1), and carbonic anhydrase 12 (Car12) was high in the absence of Grim-19. Abcb5 is associated with drug resistance in certain melanomas (29) . Pou2f2 (Oct2) promotes resistance to apoptosis via Bcl2 induction (30) . Olig1, a basic helix-loop-helix transcription factor, is associated with the development of certain forms of brain tumors (31) . Car12 has been implicated in breast and cervical tumor development (32, 33) . This analysis also showed that the expression of certain IFN-stimulated genes (ISGs)-the IFNinduced GTP-binding proteins Mx1 and Mx2 and 2′-5′ oligoadenylate synthases 1A (Oas1a), 1E (Oas1e), and 1H (Oas1h)-is down-regulated in the absence of Grim-19. These observations are consistent with a previous study that reported repression of several IFN-inducible genes in the presence of STAT3C (34) . In light of these findings, we predict that hyperactivated Stat3 resulting from the loss of Grim-19 mediates such negative effects on ISGs. The relevance to tumor growth of other genes in this analysis is unclear at this stage.
Discussion
It now is clear that the activation of STAT3C, which promotes the growth of cancer cells, requires inactivation/activation of some other factors, apart from phosphorylation of its Y 705 . Three STAT3 inhibitors, suppressor of cytokine signaling 3 (SOCS3), protein inhibitor of activated STAT3 (PIAS3), and GRIM-19, are known to date. Tumor-suppressive roles have not been established for SOCS3 and PIAS3. Deletion of Socs3, which is an inhibitor of Janus kinases, led to defective IL-6 signaling and alterations in IFN-induced responses (35, 36) , whereas its overexpression caused resistance to IFN response (37) . The biology of the PIAS3 protein is not fully clear. Originally described as a STAT3-specific inhibitor (38) , it also blocks the microphthalmia transcription factor (39), acts as a SUMOylation cofactor for nuclear receptors, and binds to the intracellular domain of ErbB4 to enhance its nuclear retention (40) . Unlike SOCS3 and PIAS3, which block the acute cytokineinduced responses, GRIM-19 blocks oncogene-induced cellular transformation and acts against chronically active STAT3 (41). Thus, of these three STAT3 inhibitors, GRIM-19 is a likely tumor suppressor.
A potential tumor-suppressor-like activity of GRIM-19 was indicated in our early studies, which found that the same DNA viral oncogenes that inactivate p53 also blocked GRIM-19-induced antigrowth effects. For example, the vIRF1 protein of Kaposi's sarcoma-associated herpesvirus, simian vacuolating virus 40 T antigen, and human papilloma virus-E6 bind to GRIM-19 and block its antitumor effects (42) . In high-risk human papilloma virus-positive advanced SCCs of the uterine cervix, loss of GRIM-19 correlated with a loss of tumor-suppressor p53 expression (43) . In these tumors, p53 is targeted to ubiquitin/ proteasome-dependent degradation by the viral E6 oncoprotein in association with a cellular enzyme, E6AP. GRIM-19 disrupted the formation of E6/E6AP complex to prevent p53 degradation and enforce growth suppression (43) . Furthermore, our studies (14) and another independent report (15) showed that GRIM-19 targets transcription factor STAT3 for inhibition via direct binding. GRIM-19 antagonizes cellular transformation by an experimentally engineered STAT3C (41) and suppresses growth of cell lines expressing high levels of endogenous STAT3C. Direct administration of a plasmid expressing GRIM-19 into tumors also caused regression (44) . GRIM-19 suppressed not only tumor growth but also neoangiogenesis (19) . Consistent with its tumor-suppressive characteristics, we and others have documented a loss of GRIM-19 expression in a number of primary human cancers of the kidney, colon, brain, prostate, lung, and cervix (19, (44) (45) (46) (47) (48) (49) (50) (51) . More recently, we have identified functionally inactivating somatic mutations in GRIM-19 in primary human oral SCCs (16) . GRIM-19 mutations also have been reported in the Hürthle cell tumors of human thyroid (52) . More importantly, all GRIM-19 mutants described to date are ineffective in blocking STAT3 function(s), thus underscoring the importance of GRIM-19 as a tumor suppressor in humans. Previously, the tumor-suppressive activity of GRIM-19 had been established by (i) growth suppression in several different tumor cell lines upon its restoration, and (ii) its defective expression in primary tumors. Therefore, it is important to know if its loss in the context of a whole animal contributes to tumor development.
Our earlier attempts to knock out the Grim-19 gene yielded no live pups, consistent with another independent study that reported embryonic lethality at the preimplantation blastocyst stage (53) . Cells recovered from the knockout blastocysts showed a suboptimal assembly of ETC complexes I and IV (53) . Nonetheless, these studies highlighted the biological importance of GRIM-19 in mitochondrial ATP generation. To circumvent these problems in this study, we generated a mouse that bore a modified Grim-19 allele that permits its conditional inactivation. Our repeated attempts to generate pan-tissue-deleted mice using a deleter stain, Meox2
CreSor , which knocks out the target gene later in the embryogenesis (i.e., during somite formation), did not yield any live embryos or pups. As does Grim-19 deletion, Stat3 deletion results in embryonic lethality (54) , although not at same embryonic stage. Thus, Grim-19 appears to be important for animal development. One major defect was the defective assembly of mitochondrial ETC complexes I, IV, and V in the absence of Grim-19 ( Fig. 9 F-H) . Together, these observations suggest that Grim-19 loss causes low ATP production in the developing embryo, leading to death in utero (53) . Indeed, Grim-19 −/− cells consumed less oxygen, used more glucose, and produced higher amounts of lactic acid than did the wild-type cells, suggesting a switch to Warburg respiration. Despite these notable effects on oxidative phosphorylation, deletion of Grim-19 in the adult skin did not affect skin organization and/or differentiation significantly, because all markers of skin were present equivalently in Grim-19 −/− and control samples (Fig. 2) . Under current experimental conditions, deletion of Grim-19 alone did not result in tumor development in the skin at 19 mo. It is possible that these mice may develop tumors as they age. However, the knockout mice are extremely susceptible to skin tumorigenesis when exposed to DMBA/TPA. Many of these tumors looked like keratoacanthomas in transition to poorly differentiated SCCs. Complementing our data, an earlier study showed that skin-specific deletion of Stat3 suppressed skin tumors in response to DMBA/TPA, indicating the critical role of Stat3 in skin tumorigenesis (26) . The level of Stat3 activation was significantly high in the Grim-19-deficient tumors, and most of the Stat3 was found in the nuclei. Active Stat3 levels increased in 70% of the Grim19 −/− tumors analyzed. However, overexpression of STAT3C alone was insufficient for skin tumorigenesis unless accompanied by treatment with DMBA/TPA (55), suggesting that the inactivation of another tumor suppressor is required. Some recent studies reported the presence of Stat3 in mitochondria of certain cell types and in certain Ras-transformed cells. However, we were unable to find Stat3 in the mitochondria of either Grim-19 −/− or Grim-19 +/+ tumors. Consistent with oncogenic alterations in the skin, activated Stat3 levels also were increased, resulting in an increased expression of cyclin D1 (Fig. 4) , a transcriptional target of STAT3 (56) . We recently reported that acquisition of GRIM-19 mutations or loss of its expression in primary human tumors unleashes STAT3 activity and up-regulation of cyclin D1 (16) . Indeed, pharmacological interference with Stat3 function suppressed tumorigenesis in Grim-19 −/− mice (Fig. 5A) . Conversely, overexpression of STAT3C significantly promoted tumorigenesis in these mice (Fig. 5D ). Taken together, these observations indicate important roles for GRIM-19 and STAT3 (57) early in tumorigenesis.
Interestingly, almost all the cyclin D1 is found in the nuclei of the tumors from Grim19 −/− mice. In contrast to its canonical role in the cell cycle as a cofactor for certain cyclin-dependent kinases (CDKs), in other models (58, 59) , in some cases cyclin D1 acts as a transcriptional coactivator promoting or suppressing gene expression, apparently independently of CDKs (60) . Furthermore, certain cyclin-CDK complexes participate in splicing as well as transcription (61) and thus may alter gene expression in cancer cells. In addition to cyclin D1, many growth-promoting genes such as Bcl2-l1, Ccnb1, Ccnd1, Cdk1, and Dhfr also were highly induced in these tumors. Notably, the first three are known to be regulated by STAT3 (14) . Similar to Grim-19 −/− mice, Stat1 −/− mice did not develop skin tumors unless exposed to chemical carcinogens (62) , indicating that loss of a tumor suppressor alone is insufficient for promoting tumor formation. Grim19 −/− tumors appear to be poorly differentiated, as shown by the expression of Sox2 (in 30% of tumors), and Ezh2 (in 30% of tumors). Other markers of undifferentiated state such as Nanog and Oct 4 were undetectable in our hands. EZH2 is a histone 3 lysine N-methyl transferase belonging to the polycomb group of proteins which causes chromatin repression and is known be up-regulated in a number of human cancers (63) . A recent study showed that arsenic-induced carcinogenesis involves the activation of Ezh2 via the JNK/STAT3/Akt pathway (64) . Such observations indicate a potential connection between STAT3/GRIM-19 and Ezh2, such that a loss of GRIM-19 may promote Ezh2 up-regulation (Fig. 4E) . In some nonmelanoma human skin cancers, β-catenin levels are elevated (65) and have been implicated in DMBA/TPA- induced skin tumor development (66) . In 18% of tumors developed in Grim19 −/− mice we observed a rise in β-catenin protein (Fig. 4G) . Thus, β-catenin expression appears to be a minor pathway activated in Grim19 −/− tumors. Recent studies with skin-specific Stat3 knockout and transgenes have shown that Stat3 plays a key role in DMBA/TPAinduced carcinogenesis, resulting in the development of SCCs (26, 55) . Indeed, a positive correlation between phospho-STAT3 and the invasive potential of nonmelanoma cutaneous SCCs has been found in human studies (22) . Similarly, in head and neck SCCs STAT3 is critical for initiation and progression of disease (57) . As mentioned previously, GRIM-19 mutants from human oral SCCs were significantly weak at inhibiting STAT3 activity (16) . Last, E-cadherin expression was reduced significantly in the tumors that developed in Grim19 −/− mice as compared with those in wild-type mice. Such reduction in E-cadherin is consistent with the invasive phenotype of these SCCs (25) . Together these data suggest that deregulation of STAT3 is a clear first step in carcinogenesis, thus placing Grim-19 and Stat3 in the early stages of carcinogenesis. In this regard, Grim-19 −/− mice behaved like Stat1 −/− mice, which also are hypersensitive to chemical carcinogenesis. However, unlike STAT1, loss of expression and mutations in GRIM-19 occur in human tumors. One surprising observation that emerged from our studies is that even a monoallelic loss of Grim-19 is sufficient for tumor development. Mice bearing single alleles of many tumor suppressors such as Beclin1 (67, 68) , Mapsin (69), Pten (70), Atr (71), Anx7 (72), and Blm (73) are similarly prone to tumor development.
Tumor arising in DMBA/TPA-treated skins generally carry mutations in the Harvey rat sarcoma (Hras) gene, particularly in one of the amino acids at codons 12 or 61, which code for Gly and Gln, respectively (74) . Sequencing of the Hras gene from six different tumors each from wild-type and Grim-19 −/− mice revealed acquisition of heterozygosity in Hras gene. Irrespective of the Grim-19 genotype, all tumors except one bore mutations at codon 61, where Gln was replaced by either Leu or His. Only one tumor had a Gly-to-Val substitution at codon 12. Thus, loss of Grim-19 does not seem to alter the spectrum of Hras mutations. Importantly, Hras mutation alone is insufficient to promote skin tumorigenesis without another genetic change. Last, under the conditions used in our study, only 68% of Grim-19 −/− mice developed tumors. This result probably does not reflect a lack of 100% penetrance of the gene effect, because laboratory strains of mice respond differently to DMBA/TPA. The DMBA/ TPA sensitivity of different strains of mice is in the following order: Sencar > NMR1 > CD1 > C57BL6, with Sencar being the most sensitive (74) . Despite the weaker response of the C57BL6 stain to DMBA/TPA, we were able to observe distinct differences between the wild-type and Grim-19 −/− mice. The mitochondrial ATP production occurs via four welldefined ETC complexes plus the ATP synthase. We found that loss of Grim-19 dramatically affected mitochondrial respiration and glucose metabolism (Figs. 9 and 10 ). After Grim-19 deletion, the assembly of nearly all ETC complexes was defective, with a rise in complex III (Fig. 9 E-G) . Earlier, it was reported that in certain primary human renal cell carcinomas (RCCs), loss of ETC activity resulting from a decline in the levels of complexes II-V was associated with tumor aggressiveness (75) , although the reason for the association was unknown. Importantly, we have reported that a loss of GRIM-19 (present in complex I) in RCCs promotes tumor growth (76) . The mammalian ETC complex I consists of ∼46 subunits, 14 of which form the catalytic core (77) . Seven of the core subunits are derived from the mitochondrial and nuclear genomes. The rest, the so-called "accessory subunits," are derived primarily from the nuclear genome and are suggested to guard the integrity of this complex. For example, the NDUFA4 subunit stimulates NADH-ubiquinone reductase activity (77) . Consistent with these observations, we observed a significant loss of all complexes, with a more dramatic effect on complexes I and IV. Thus, GRIM-19 appears to guard the in- tegrity of ETC complexes, because its absence affected not only complex I but also the others. Such loss may be secondary to the inability to form complex I. Taken together, these findings suggest that the loss GRIM-19 may be an early step in ETC dysfunction. Biologically, inhibition of ETC resulting from mutations in one of its subunits or in their assembly or from RNAi-mediated suppression causes resistance to apoptosis (see ref. 78 for a review). For example, mutations in the SDH-B/C/D, the components of complex II, are found commonly in certain pheochromocytomas, paragangliomas, and RCCs (79, 80) and are associated with resistance to apoptosis and tumorigenesis (78) . In agreement with these observations, we have demonstrated in previous studies (13, 16, 76 ) that loss of GRIM-19 expression or mutations involving GRIM-19 cause resistance to apoptosis and promotion of cell growth. Although some recent studies have reported Stat3 as a necessary protein for complex II function in certain Ras-transformed cells (81), we have not observed mitochondrial Stat3 in either wild-type or Grim-19 −/− tumors. Importantly, it appears that GRIM-19 loss favors a dependence on glycolysis and an avoidance of apoptosis, two major landmarks of an evolved cancer cell.
Our analysis of genes coding for glycolysis showed that Aldoa, Gckr, Pkm2, and Pdk2 are induced strongly in the absence of Grim-19. Aldolase (A, B, and C isoforms) catalyzes the reversible cleavage of fructose-1, 6-(bis) phosphate and fructose 1-phosphate to dihydroxyacetone phosphate and either glyceraldehyde-3-phosphate or glyceraldehyde, respectively. Several studies have shown that high ALDOA levels drive cell proliferation (82, 83) . Notably, a nonglycolytic nuclear role for ALDOA in transcription (83) and a role in cytokinesis, independent of its catalytic function (82) have been suggested, although the pertinent target factors have not been identified. The PKM gene codes two alternately spliced gene products, M1 and M2. The latter is found primarily during embryonic development but reappears in a number of human cancers and aids in lactate production. Interestingly, recent studies show that this protein modulates histone phosphorylation (84) and acts as a coactivator for several transcription factors such as HIF1, HIF2, β-catenin (85), Oct4, and STAT3 (86) . Dimeric PKM2, a form found predominantly in the nuclei, unlike the tetrameric form found in the cytoplasm, directly phosphorylates STAT3-Y 705 , independent of JAKs and Src, to promote transcription of cellular genes and tumor formation (86) . Based on these observations, we suggest that Pkm2 may serve as a nuclear transcriptional modulator of Stat3 in the absence of Grim-19.
Indeed, nuclear PKM2 has been suggested to be a poor prognosticator for certain head and neck SCCs (87) . Four isozymes of PDK are described to date. Among these, expression of PDK1, which promotes lactate production and hypoxia, is associated with a poor prognosis for certain head and neck SCCs (88) . Chronic exposure of keratinocytes to cigarette smoke induces PDK2 expression, hypoxia, and increased glycolysis (89) . The tumor suppressor p53 negatively regulates PDK2, indicating its potent tumor-promoting function (90) . These observations are consistent with the elevated expression of Pdk2 in the absence of Grim-19. This elevated expression appears to be a selective effect on Pdk2, given the down-regulation of Pdk4 in the absence of Grim-19 (Fig. 10E) . It has been reported that PDK4 is downregulated in presence of STAT3 (34) . That Stat3 activity goes up in the absence of Grim-19 is consistent with the repression of Pdk4. The role of GCKR in cancer is unknown, except that a single polymorphism associated with diabetes is associated with an increased risk for the development of pancreatic cancer (91) .
Loss of Grim-19 appears to alter tumor microenvironment. Enhanced glycolysis in the absence of Grim-19 led to the production of lactic acid (Fig. 9) . Lactic acid secreted by tumors is known to promote tumor growth by inducing inflammation, angiogenesis, tumor cell motility, and immune escape (92) . In contrast, tumor-derived lactic acid has been shown to suppress T cells (93) . Activated T cells themselves generate energy through glycolysis. When tumor cells release large quantities of lactate into their microenvironment, immune cells cannot rid themselves of their own lactate, because cellular lactate secretion is dependent on the ratio of intra-to extracellular concentration (92) . As a result, lymphocytes may be inactivated by lactate. In summary, our studies provide compelling evidence that Grim-19 has a major role in tumor suppression by acting as an essential regulator of antioncogenic transcription and metabolism.
Materials and Methods
All experimental procedures were approved by the University of Maryland, Baltimore, Institutional Animal Care and Use Committee. All data were subjected to Student's paired t test. A P value < 0.05 was considered significant in all experiments. Detailed materials and methods are presented in the SI Appendix.
